Y90 Radioembolization in chemo-refractory metastastic, liver dominant colorectal cancer patients: outcome assessment applying a predictive scoring system

Table 3 Cox regression of potential factors to predict survival

Cox regression	Hazard	(95 % CI)	Univariate P	Multivariate P
Age	1.02	(1.00–1.04)	0.239
Sex‘	0.76	(0.50–1.14)	0.179
Karnofsky index	0.98	(0.95–0.99)	0.014*	0.037**
Resection/RFA‘	0.90	(0.56–1.44)	0.658
Oxaliplatin + 5-FU‘	1.44	(0.91–2.26)	0.118
Irinotecan + 5-FU‘	1.41	(0.82–2.46)	0.216
Capecitabine‘	1.24	(0.79–1.94)	0.344
Bevacizumab‘	0.87	(0.58–1.30)	0.492
Cetuximab‘	1.26	(0.85–1.87)	0.243
Overall chemotherapy lines	1.14	(0.94–1.37)	0.179
UICC staging	1.01	(0.79–1.30)	0.286
Tumor grading	0.90	(0.64–1.28)	0.434
Lung metastases‘	1.53	(0.85–2.74)	0.155
Lymphatic metastases‘	1.60	(0.91–2.80)	0.100*	0.204
Bone metastases‘	2.51	(0.89–7.13)	0.083*	0.083
Hepatic tumor load	1.05	(1.03–1.06)	<0.001*	0.001**
CEA serum level	1.00	(1.00–1.00)	0.002*	0.023**
CA19-9 serum level	1.00	(1.00–1.00)	<0.001*	<0.001**
Bilobar Y90 RE‘	0.89	(0.45–1.77)	0.740
Unilobar Y90 RE‘	0.74	(0.35–1.55)	0.426
Sequential lobar Y90 RE‘	0.82	(0.40–1.66)	0.775
Y90 RE sessions per patient	0.95	(0.72–1.24)	0.692
Total activity per patient	1.00	(0.99–1.00)	0.276

Results in the univariate analysis (*p < 0.1) were included in the multivariate analysis (**p < 0.05). Binary factors are marked (‘), other variables are ordinal or continuous

ISSN: 1471-2407